Related references
Note: Only part of the references are listed.Impact of intravesical instillation of a novel biological response modifier (P-MAPA) on progress of non-muscle invasive bladder cancer treatment in a rat model
Wagner J. Favaro et al.
MEDICAL ONCOLOGY (2022)
OncoTherad® (MRB-CFI-1) nano-immunotherapy reduced tumoral progression in non-muscle invasive bladder cancer through activation of Toll-like signaling pathway
I. B. Reis et al.
TISSUE & CELL (2022)
Evolution of immunotherapy in the treatment of non-muscle-invasive bladder cancer
Niyati Lobo et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2022)
Effects of combined OncoTherad immunotherapy and probiotic supplementation on modulating the chronic inflammatory process in colorectal carcinogenesis
Sabrina Karen Reis et al.
TISSUE & CELL (2022)
Safety and Efficacy of OncoTherad Nano-immunotherapy in Patients with Non-Muscle Invasive Bladder Cancer
J. C. C. Alonso et al.
7TH NANOSAFE INTERNATIONAL CONFERENCE ON HEALTH AND SAFETY ISSUES RELATED TO NANOMATERIALS FOR A SOCIALLY RESPONSIBLE APPROACH, NANOSAFE 2020 (2021)
Harnessing the immune system to fight cancer with Toll-like receptor and RIG-I-like receptor agonists
Carole Bourquin et al.
PHARMACOLOGICAL RESEARCH (2020)
Biogenic silver nanoparticles: In vitro and in vivo antitumor activity in bladder cancer
Luiz Alberto Bandeira Ferreira et al.
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS (2020)
Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy
Yun Yang et al.
IMMUNOLOGY LETTERS (2020)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
Lesley Seymour et al.
LANCET ONCOLOGY (2017)
RANK-RANKL signalling in cancer
Nathalie Renema et al.
BIOSCIENCE REPORTS (2016)
Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier
Patrick Vianna Garcia et al.
BMC CANCER (2016)
Toll-Like Receptor Signaling and Its Inducible Proteins
Takashi Satoh et al.
MICROBIOLOGY SPECTRUM (2016)
Use of Cause-and-Effect Analysis to Design a High-Quality Nanocytotoxicology Assay
Matthias Roesslein et al.
CHEMICAL RESEARCH IN TOXICOLOGY (2015)
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
Leticia Corrales et al.
CELL REPORTS (2015)
Recent advances in the field of anti-cancer immunotherapy
Henrique Neves et al.
BBA CLINICAL (2015)
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
Seng-Ryong Woo et al.
IMMUNITY (2014)
Standing the test of time: targeting thymidylate biosynthesis in cancer therapy
Peter M. Wilson et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Interferon-Gamma-Induced Nitric Oxide Inhibits the Proliferation of Murine Renal Cell Carcinoma Cells
David J. Tate et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Intratumoral Injection of CpG Oligonucleotides Induces the Differentiation and Reduces the Immunosuppressive Activity of Myeloid-Derived Suppressor Cells
Yuko Shirota et al.
JOURNAL OF IMMUNOLOGY (2012)
IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors
Heba A. Alshaker et al.
CANCER CELL INTERNATIONAL (2011)
IFN-γ-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer
Matteo Martini et al.
VACCINE (2010)
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Louis M. Weiner et al.
NATURE REVIEWS IMMUNOLOGY (2010)
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Eric Van Cutsem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
RANK/RANKL: Regulators of Immune Responses and Bone Physiology
Andreas Leibbrandt et al.
YEAR IN IMMUNOLOGY 2008 (2008)
Guideline for the management of nonmuscle invasive bladder cancer (Stages Ta, T1, and Tis): 2007 update
M. Craig Hall et al.
JOURNAL OF UROLOGY (2007)
Cross-talk between T cells and innate immune cells is crucial for IFN-γ-dependent tumor rejection
Zhiguang Li et al.
JOURNAL OF IMMUNOLOGY (2007)
Cancer statistics, trends, and multiple primary cancer analyses from the surveillance, epidemiology, and end results (SEER) program
Matthew J. Hayat et al.
ONCOLOGIST (2007)
Inhibition of NF-κB in cancer cells converts inflammation-induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression
JL Luo et al.
CANCER CELL (2004)
Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity
A Bohle et al.
JOURNAL OF UROLOGY (2003)
Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis
BV Offersen et al.
BRITISH JOURNAL OF CANCER (2002)
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
V Shankaran et al.
NATURE (2001)
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-γ
H Takayanagi et al.
NATURE (2000)
Share Paper
